MX2021011224A - Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. - Google Patents
Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria.Info
- Publication number
- MX2021011224A MX2021011224A MX2021011224A MX2021011224A MX2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- treating
- patient
- apah
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Existe un método para tratar o prevenir la hipertensión arterial pulmonar (HAP) o la hipertensión arterial pulmonar asociada (HAPA) en un paciente. El método incluye una etapa en que se administra al paciente una cantidad terapéuticamente eficaz de uno o más compuestos: 8-(2-amino-6-((R)-1-(5-cloro-[1,1'-bifenil]- 2-il)-2,2,2-trifluoroetoxi)pirimidin-4-il)-2,8- diazaespiro[4.5]decano-3-carboxilato de (S)-etilo o una sal farmacéuticamente aceptable del mismo, o el ácido (S)-8-(2-amino-6-((R)-1-(5-cloro-[1,1'-bifenil]-2-il)-2,2,2-trifl uoroetoxi)pirimidin4-il)-2,8-diazaespiro[4.5]decano-3-carboxílic o o una sal farmacéuticamente aceptable del mismo, o una combinación de los anteriores. También existe un método para tratar o prevenir la HAP o la HAPA en un paciente, administrando sistémicamente una cantidad terapéuticamente eficaz de un inhibidor de TPH1, de aproximadamente 1 mg/kg/día a aproximadamente 50 mg/kg/día. Existe un método para tratar la HAP o la HAPA en un paciente con una sola dosis diaria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962819162P | 2019-03-15 | 2019-03-15 | |
PCT/IB2020/000177 WO2020188352A1 (en) | 2019-03-15 | 2020-03-13 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011224A true MX2021011224A (es) | 2021-12-10 |
Family
ID=71092560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011224A MX2021011224A (es) | 2019-03-15 | 2020-03-13 | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. |
Country Status (9)
Country | Link |
---|---|
US (2) | US11576915B2 (es) |
EP (1) | EP3938043A1 (es) |
JP (1) | JP2022525202A (es) |
KR (1) | KR20210139293A (es) |
CN (1) | CN113784717A (es) |
AU (1) | AU2020244278A1 (es) |
CA (1) | CA3133589A1 (es) |
MX (1) | MX2021011224A (es) |
WO (1) | WO2020188352A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020099926A1 (en) * | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
CN113557022A (zh) * | 2019-01-30 | 2021-10-26 | 阿尔塔万特科学公司 | 用罗达司他乙酯治疗肺动脉高压的给药方案和方法 |
US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2170397A1 (en) * | 2007-07-11 | 2010-04-07 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
US9399741B2 (en) | 2013-10-09 | 2016-07-26 | Uop Llc | Methods and apparatuses for desulfurizing hydrocarbon streams |
CN113227093A (zh) * | 2018-11-14 | 2021-08-06 | 阿尔塔万特科学公司 | 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法 |
WO2020099926A1 (en) | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
WO2020128608A1 (en) * | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
US20200188399A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
CN113557022A (zh) | 2019-01-30 | 2021-10-26 | 阿尔塔万特科学公司 | 用罗达司他乙酯治疗肺动脉高压的给药方案和方法 |
US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-03-13 US US16/818,236 patent/US11576915B2/en active Active
- 2020-03-13 AU AU2020244278A patent/AU2020244278A1/en not_active Abandoned
- 2020-03-13 JP JP2021555469A patent/JP2022525202A/ja active Pending
- 2020-03-13 KR KR1020217031156A patent/KR20210139293A/ko unknown
- 2020-03-13 WO PCT/IB2020/000177 patent/WO2020188352A1/en active Application Filing
- 2020-03-13 EP EP20732658.8A patent/EP3938043A1/en active Pending
- 2020-03-13 MX MX2021011224A patent/MX2021011224A/es unknown
- 2020-03-13 CN CN202080033296.0A patent/CN113784717A/zh active Pending
- 2020-03-13 CA CA3133589A patent/CA3133589A1/en active Pending
-
2023
- 2023-01-04 US US18/149,992 patent/US20240024316A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113784717A (zh) | 2021-12-10 |
WO2020188352A1 (en) | 2020-09-24 |
AU2020244278A1 (en) | 2021-09-30 |
US20240024316A1 (en) | 2024-01-25 |
US11576915B2 (en) | 2023-02-14 |
EP3938043A1 (en) | 2022-01-19 |
JP2022525202A (ja) | 2022-05-11 |
US20200289510A1 (en) | 2020-09-17 |
CA3133589A1 (en) | 2020-09-24 |
KR20210139293A (ko) | 2021-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021011224A (es) | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. | |
MX2008013578A (es) | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). | |
GB0423653D0 (en) | Pharmaceutical compounds | |
IL166413A0 (en) | Use of and some novel imidazopyridines | |
MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
CA2549801A1 (en) | Use of treprostinil to improve kidney functions | |
WO2001039762A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
WO2005007081A3 (en) | Compounds and methods for delivery of prostacyclin analogs | |
CA2793138C (en) | Hydroxybenzoate salts of metanicotine compounds | |
MX2021009055A (es) | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. | |
IL166412A0 (en) | Novel use of benzothiazole derivatives | |
MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
MX2022008342A (es) | Metodos para tratar afecciones relacionadas con el receptor de s1p1. | |
MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
WO2020128614A8 (en) | Method for treating interstital lung disease | |
US7034025B2 (en) | Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein | |
MX2022006083A (es) | Metodos para tratar afecciones relacionadas con el receptor s1p1. | |
RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
AU2016219617A1 (en) | Positively charged water-soluble prodrugs of aspirin | |
NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole |